Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

PURPOSE: This single‐center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Patients with locally advanced ESCC treated with paclitaxel‐liposome‐based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier analysis. RESULTS: Thirty‐nine patients with locally advanced ESCC were included in this study. The median follow‐up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1–45.1) months, and the 1‐, 2‐, and 3‐year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4–39.0) months, and the 1‐, 2‐, and 3‐year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis. CONCLUSION: Chemoradiotherapy using paclitaxel liposome and cisplatin is a well‐tolerated and effective treatment regimen for locally advanced ESCC.